Jean Labuschagne – Our Founder

Jean’s science is to follow his intuition in pursuit of his belief that every person, whether healthy or ill, has the right to be healthier in order to live a better life.
His vision is to develop technologies that afford individuals the opportunity to be better, both physically and mentally.

Jean has the mind of an engineer and the heart of an experimenter—always questioning what he sees. But for him it’s more than observation, it’s an investigation— a slow hunch unfolding. Through research and development, he has been able to predict what the market needs but hasn’t yet been realized in the accelerating field of neurotechnology.

In 2000, while living in Europe, Jean observed that leg ulcers caused by diabetes or trauma healed with the application of electromagnetic waves—an application of low intensity magnetic pulses. His quest to understand this process of tissue repair, which magnetic and electrical stimulation facilitated, initiated his research to better understand the role of natural bioelectric energy in the body.

Jean spent the next years exploring how minute currents of electrical pulses applied to the head could promote neuroplasticity by strengthening and developing new neural connections.
Jean questioned why noninvasive neuromodulation treatments that were used in medical clinics for the treatment of neuropsychiatric disorders—depression, chronic pain, epilepsy, anxiety, insomnia—couldn’t also be utilized to enhance and improve mental and physical performance in healthy individuals. Jean recognized that people suffering from pain and leg ulcers had a propensity for depression and anxiety along with insomnia.

By 2004, his team had researched and developed a working prototype of a personal device for the consumer market that used bioelectric processes to combine non-invasive brain stimulation along with soft tissue healing. The device received FDA 510k market clearance and Elexoma was launched.

Jean understood that through research and scientific data, personal and cultural growth resided in exploring and understanding how to create stronger and more robust neural pathways throughout the body. Over the next four years, several prototypes were developed based on the idea of using neuromodulation to improve both cognitive and physical performance.

In 2010, Jean’s research and development of handheld, noninvasive brain stimulation devices that could safely be used outside of clinical supervision got the attention of Felipe Fregni, Associate Professor of Neurology and Physical Medicine and Rehabilitation at Harvard Medical School.

In 2012, NeuroImage, a peer-reviewed scientific journal, published a paper confirming that the minute electrical impulses of Jean’s prototypes had the potential to influence brain performance. A Safety Study was done in 2013 confirming that the technology used in these devices was safe and had a potentially positive impact on cognitive function. Jean was subsequently invited to lecture at the Center for Neuromodulation at the Spaulding Rehabilitation Hospital, a Harvard Teaching and Research Facility. Eight more scientific research projects were underway at the Center on this technology. Results further validated and confirmed its safety and potential in cognitive performance, making it the most researched technology in its class by the Center. During this time Jean also founded Braingear with the sole focus to develop consumer brain stimulation devices for medical and consumer market applications.  In late 2015, Jean stepped down as Chief Visionary Officer, though he remains on the Board.
In 2015, Jean and the Spaulding Rehabilitation Hospital partnered to develop the vision for The Spaulding-Labuschagne Neuromodulation Center, a teaching facility of the Harvard Medical School. As a result, Jean is now mentored by leading scientists in the field of neuromodulation.

The center is a platform for clinical research, education, and communication of Body ElectricThink Outside the Brain. Its mission is to understand how the neural waves of energy that move throughout the body can be utilized through noninvasive neurostimulation for diagnostic applications to help treat disorders of the brain and body, and help both the unwell and the healthy to achieve an optimum level of physical and mental performance.

Jean continues to broaden the scope of his involvement in neuromodulation technologies and businesses to benefit a wider population through a greater range of new technologies and applications. His advice has already led to IP developments for the next generation of neuromodulation technologies, which will benefit patients with neurological disorders and enhance performance related technologies for the healthy consumer market.
Jean now works with the best brains in the scientific and business communities of the neuromodulation industry.